AEON Regains NYSE American Listing Compliance
AEON Biopharma has resolved deficiencies in stockholders' equity by closing a public offering, removing the '.BC' listing indicator. The capital raise supports the rollout of its ABP-450 BOTOX biosimilar.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day